A recent study indicates that individuals who stop using popular GLP-1 drugs like Wegovy and Mounjaro tend to recover lost weight much more quickly than those who stop conventional diet and exercise programs.
Research printed in a major medical journal points out that while overweight people can lose a large proportion of their total mass while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month after stopping.
"People using these drugs must be aware of the risk of fast weight regain when the medication ends," warns expert Dr. Susan Jebb.
This pace of recovery implies a return to original weight in about 18 months.
Analyzing Therapies
The analysis, which reviewed 37 of studies involving over 9,000 of patients, contrasted the results of these new drugs with older methods.
The team note that people who lose weight through diet and exercise generally see a slower weight regain—perhaps 0.1 kg a month—after stopping.
The Reason for the Quick Rebound
Nutrition scientists propose the way of the jabs accounts for the accelerated rebound.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Artificially providing the hormone concentrations several times higher than normal may cause the body to produce less of its endogenous hormone, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' means appetite is uncontrolled, making binge eating a significant risk."
An Ongoing Issue?
Medical guidelines recommend the jabs for people with weight-linked health risks, alongside prescribed lifestyle changes.
A number of clinicians say that, due to the high risk of weight regain, the therapy might need to be ongoing.
This opinion is supported by pharmaceutical companies, who say that the results "underscore the persistent character of excess weight," comparing it to managing conditions like diabetes.
User Experiences
People who have come off the medication report a intense resurgence of appetite.
"I experienced a trigger flipping and I was suddenly ravenous," recalled a patient.
This difficulty is exacerbated if patients have not developed lasting lifestyle or habit changes during therapy.
Growing Interest
Figures suggest that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with demand remaining high.
- Use is higher among women than males.
- The 40s and 50s demographic shows the greatest usage rates.
- Many obtain the medications through private healthcare rather than public health services.
In conclusion, clinicians stress that while GLP-1 drugs are powerful tools for shedding pounds, they are not a permanent solution and long-term success hinges on integrated lifestyle changes.
